Revolution Medicines daraxonrasib boosts survival in pancreatic cancer

Revolution Medicines reported that its oral targeted drug daraxonrasib nearly doubled median survival in a phase 2 trial for metastatic pancreatic cancer, extending median overall survival to 13.2 months versus 6.7 months for chemotherapy. The company said it will pursue expedited review pathways with the U.S. Food and Drug Administration (FDA).

According to company commentary and trial reports, daraxonrasib works by inhibiting RAS-driven tumor pathways, producing substantial tumor responses in a subset of patients. Revolution Medicines CEO Mark Goldsmith described the results as surprising in their magnitude; the trial also recorded notable adverse effects in some patients. Former U.S. senator Ben Sasse, who is enrolled in the study, reported significant tumor shrinkage but also visible side effects while on the drug.

Markets reacted sharply: Revolution Medicines shares leapt about 41% on the announcement, closing near $136 and lifting the company's market capitalization to roughly $27 billion. Investors appear to be repricing the company on the prospect of a higher probability of approval, expanded commercial potential for a RAS-targeting oral therapy, and renewed merger-and-acquisition interest. The stock trades under the ticker RVMD.

Clinically, the result is notable because pancreatic adenocarcinoma has remained one of the most lethal common cancers, with low five-year survival rates and limited effective systemic options. For the biotech sector, a successful oral RAS inhibitor would represent a strategic asset class and could prompt competitor and acquirer attention, as prior takeover discussions reportedly valued the company in the tens of billions.

Analysts caution that phase 2 success must be confirmed in larger randomized studies and that safety and tolerability will be central to regulatory review. Near-term catalysts include upcoming data presentations and a potential FDA filing; until confirmatory evidence and regulatory decisions materialize, share price volatility and speculative M&A talk are likely to persist. Investors should weigh clinical risk, regulatory timelines and commercial assumptions when reassessing valuation.